WO2022208269 - SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME
National phase entry:
Publication Number
WO/2022/208269
Publication Date
06.10.2022
International Application No.
PCT/IB2022/052782
International Filing Date
25.03.2022
Title **
[English]
SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME
[French]
COMPOSÉS 1-ARYL-1'-HÉTÉROARYLE SUBSTITUÉS, COMPOSÉS 1,1'-BIHÉTÉROARYLE SUBSTITUÉS ET LEURS MÉTHODES D'UTILISATION
Applicants **
ARBUTUS BIOPHARMA CORPORATION
25th Floor, 700 West Georgia Street
Vancouver, British Columbia V7Y 1B3, CA
Inventors
AHUJA, Vijay
301 Trinity Court, Apt. 1
Princeton, New Jersey 08540, US
COLE, Andrew G.
65 Rocky Brook Road
Cranbury, New Jersey 08512, US
DORSEY, Bruce D.
1213 Meetinghouse Road
Ambler, Pennsylvania 19002, US
FAN, Yi
40 Bittersweet Drive
Doylestown, Pennsylvania 18901, US
HEFFERNAN, Gavin D.
616 East 6th Street
Florence, New Jersey 08518, US
KAKARLA, Ramesh
11584 Jaguar Court
San Diego, California 92131, US
KULTGEN, Steven G.
1526 Russett Drive
Warminster, Pennsylvania 18974, US
NGUYEN, Duyan
106 Cypress Drive
Ambler, Pennsylvania 19002, US
OZTURK, Seyma
696 Holland Road
Southampton, Pennsylvania 18966, US
QUINTERO, Jorge
819 Marlowe Road
Cherry Hill, New Jersey 08003, US
SOFIA, Michael J.
3066 Antler Drive
Doylestown, Pennsylvania 18902, US
Priority Data
63/167,440
29.03.2021
US
63/291,666
20.12.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CIPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 14577 | |
| EPO | Filing, Examination | 37276 | |
| Japan | Filing | 594 | |
| South Korea | Filing | 608 | |
| USA | Filing, Examination | 30710 |
Total: 83765 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure provides substituted 1-ary 1-1'-heteroarvl compounds, substituted 1,1 '-biheteroaryl compounds, analogues thereof, and compositions comprising the same. In one aspect, the compounds provided can be used to treat, ameliorate, and/or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient. In another aspect, the compounds provided can be used to treat, ameliorate, and/or prevent cancer in a patient. Compounds provided are of formula (I): (I) wherein: A is (AA) or (BB)[French]
La présente divulgation concerne des composés 1-aryl-1'-hétéroaryle substitués, des composés 1,1'-bihétéroaryle substitués, leurs analogues et des compositions les comprenant. Selon un aspect, les composés décrits dans la divulgation peuvent être utilisés pour traiter, atténuer ou prévenir des infections par le virus de l'hépatite B (VHB) et/ou le virus de l'hépatite D (VHD) chez un patient. Selon un autre aspect, les composés décrits dans la divulgation peuvent être utilisés pour traiter, atténuer et/ou prévenir le cancer chez un patient.